COMMUNIQUÉS West-GlobeNewswire
-
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
25/04/2024 - 15:00 -
Precision Optics Announces Receipt of $1.26 Million Follow On Production Order from Large Defense Company
25/04/2024 - 15:00 -
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
25/04/2024 - 15:14 -
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
25/04/2024 - 15:15 -
Using AI to Improve Diagnosis of Rare Genetic Disorders
25/04/2024 - 15:19 -
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
25/04/2024 - 15:29 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
25/04/2024 - 15:30 -
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
25/04/2024 - 16:00 -
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25/04/2024 - 16:00 -
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
25/04/2024 - 16:44 -
Ibogaine Treatment for Borderline Personality Disorder Launched by Ibogaine By David Dardashti
25/04/2024 - 16:54 -
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
25/04/2024 - 11:00 -
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
25/04/2024 - 11:00 -
Orion Group Interim Report January–March 2024
25/04/2024 - 11:00 -
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25/04/2024 - 12:00 -
Nexstim Plc: Managers’ Transactions, Niemistö
25/04/2024 - 12:00 -
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
25/04/2024 - 12:00 -
MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)
25/04/2024 - 12:01 -
Nexstim Plc: Managers’ Transactions, Weckroth
25/04/2024 - 12:05
Pages